Thermo Fisher Scientific CD30/TNFRSF8 (Hodgkin and Reed-Sternberg Cell Marker) Monoclonal Antibody (rCD30/412)

Applications

Immunohistochemistry (Paraffin) (IHC (P))

• Assay-dependent

Immunohistochemistry (PFA fixed) (IHC (PFA))

• 1–2 µg/mL

Product Specifications

Target Information

CD30 (Ki-1, TNF Receptor Superfamily Member 8) is a type I transmembrane glycoprotein belonging to the TNF receptor superfamily. It was first identified as a surface antigen of Hodgkin and Reed-Sternberg cells using monoclonal antibody Ki-1.
The ligand for CD30 is CD30L (CD153), and their interaction mediates various cellular responses including proliferation, activation, differentiation, and apoptosis.

CD30 plays a critical role in the pathophysiology of Hodgkin’s disease and other CD30+ lymphomas. It acts as a costimulatory molecule in thymic negative selection and is expressed on Hodgkin’s and Reed-Sternberg cells, some non-Hodgkin’s lymphomas (e.g., Burkitt’s lymphoma), virus-infected T and B cells, and activated normal T and B cells.

In T cells, CD30 is expressed on subsets producing Th2-type cytokines and on CD4+/CD8+ thymocytes co-expressing CD45RO and IL4 receptor. The soluble form (sCD30) serves as a marker of Th2 immune response.
TRAF2 and TRAF5 interact with CD30 to activate NF-kappaB signaling. CD30 positively regulates apoptosis and limits proliferation of autoreactive CD8 effector T cells, contributing to autoimmunity protection.

Two alternatively spliced transcript variants encoding distinct isoforms have been reported. CD30 is expressed by mononuclear cells in Hodgkin’s lymphoma, Reed-Sternberg cells, and most Anaplastic Large Cell Lymphomas (ALCL), as well as embryonal carcinomas.

For Research Use Only. Not for use in diagnostic procedures. Not for resale without express authorization.